8-K 1 form8kinvestorconfjan132016.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) – January 13, 2016

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania |  | 1-8036 |  | 23-1210010
(State or other jurisdiction of Incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA |  |  |  | 19341-0645
(Address of principal executive offices) |  |  |  | (Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

Item 7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1 is a copy of the presentation to be used by West management at the following investor conferences:

• | 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 13, 2016;

• | CJS Securities 16th Annual New Ideas for the New Year Conference in New York, New York on January 13, 2016; and

• | LEERINK Partners’ 5th Annual Global Healthcare Conference in New York, New York on February 10-11, 2016.

A copy of the presentation materials will be available for 30 days through the Investors link on http://www.westpharma.com.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.

(d) | Exhibit No. | Description
| Exhibit 99.1 | West Pharmaceutical Services, Inc. Investor Presentation.

2

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| WEST PHARMACEUTICAL SERVICES, INC. |
| /s/ William J. Federici |
| William J. Federici |
| Senior Vice President and Chief Financial Officer |
January 13, 2016 |  |

3

EXHIBIT INDEX

Exhibit No. |  | Description
99.1 |  | West Pharmaceutical Services, Inc. Investor Presentation.

4